Baillie Gifford & Co
RGNX icon

Baillie Gifford & Co’s Regenxbio RGNX Stock Holding History

Baillie Gifford & Co’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-817
Closed -$15.4K – 412
2023
Q1 		$15.4K Buy
817
+65
+9% +$1.44K ﹤0.01% 365
2022
Q4 		$17.1K Hold
752
– – ﹤0.01% 355
2022
Q3 		$20K Hold
752
– – ﹤0.01% 336
2022
Q2 		$19K Hold
752
– – ﹤0.01% 346
2022
Q1 		$25K Buy
+752
New +$20.9K ﹤0.01% 342

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Baillie Gifford & Co's RGNX Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Regenxbio (RGNX) in Q2 2023, closing a stake of 817 shares — an estimated $15.4K sold.

Baillie Gifford & Co first reported a position in RGNX in Q1 2022 and held it in 5 quarters. The position peaked at $25K in Q1 2022. 166 funds tracked by Wall St. Rank hold RGNX as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Regenxbio position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 817 Regenxbio shares in Q2 2023, an estimated $15.4K.
  • Baillie Gifford & Co first reported a position in Regenxbio in Q1 2022 and held it in 5 quarters.
  • Baillie Gifford & Co's Regenxbio position peaked at $25K in Q1 2022.
  • 166 funds tracked by Wall St. Rank held Regenxbio as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.